Tango Therapeutics, Inc. (TNGX) shares dropped 16.93 percent to $20.66, down $4.21 on Friday, after the biotechnology company reported a wider first-quarter loss, as collaboration revenue fell to zero.
The stock is currently trading at $20.66, compared with a previous close of $24.87 on the Nasdaq. It opened at $23.10 and traded between $20.60 and $23.30 during the session, with volume reaching 1.68 million shares, below the average daily volume of 3.35 million shares.
Collaboration revenue was $0 in the first quarter of 2026, compared with $5.4 million in the same period last year. Net loss widened to $45.5 million, or $0.32 per share, from $39.9 million, or $0.36 per share, a year earlier. Loss from operations increased to $48.8 million from $42.5 million.
Tango Therapeutics shares have traded between $1.40 and $28.41 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.